Mucosal Immunity
25.4K views | +11 today
Follow
 
Rescooped by Gilbert C FAURE from Virus World
onto Mucosal Immunity
January 29, 1:26 PM
Scoop.it!

Why the ‘Ferrari of Viruses’ is Surging Through the Northern Hemisphere - Science

Why the ‘Ferrari of Viruses’ is Surging Through the Northern Hemisphere - Science | Mucosal Immunity | Scoop.it

The “Ferrari of viruses” is having a banner season. Norovirus, which races through cruise ships, homes, and long-term care facilities, is experiencing a remarkable winter surge in the Northern Hemisphere, sending large numbers of people racing to the bathroom and many others to the hospital, and in rare cases, proving fatal. In the United States, for example, 91 outbreaks of the intestinal virus occurred in the first week of December 2024, far above the previous maximum, 65, for the same week between 2010 and 2024. And levels of its genes in U.S. wastewater are an order of magnitude above last year. “The early data for the early part of the season is certainly supporting that we’re going to have a pretty intense norovirus year,” says Lisa Lindesmith, who studies the virus at the University of North Carolina (UNC) at Chapel Hill. Some of the surge may be due to a new variant of the virus, unfamiliar to many people’s immune systems, and the resumption of cruises and other gatherings that the COVID-19 pandemic interrupted. And there’s no vaccine anywhere in sight: The most advanced candidate just failed a key trial and others won’t be ready for several years. Norovirus thrives in cold climes, causing explosive diarrhea and vomiting that typically only last for a day. But several weeks after people recover, they can still shed the virus, and it can remain infectious for long periods on surfaces. It’s notoriously resistant to many disinfectants, and studies in adult volunteers have shown just a trace of virus is enough to sicken a person. Oysters are also a source of infection, because the filter-feeding mollusks concentrate the virus from contaminated water in their tissues. U.S. health officials issued several warnings about infected oysters in December, and France has banned oyster harvesting in certain regions because of norovirus outbreaks.

 

For most people the virus is a rapidly passing misery that creates the wrong kind of unforgettable memories from a wedding or a holiday gathering. But, “It can be pretty severe,” says Mary Estes, a virologist at the Baylor College of Medicine who is a leading researcher in this small field. Although norovirus-related mortality is low in wealthy countries, it kills an estimated 200,000 young children in the developing world each year. Even in the U.S., it’s the leading cause of hospitalization for diarrheal disease, hitting young children and the elderly particularly hard. Immunocompromised people, particularly cancer patients on chemotherapy or transplant recipients taking antirejection drugs, can have chronic infections that last for months or even years. Many sickened people also miss work, globally leading to an estimated $60 billion in annual losses. Given that symptoms quickly resolve in most cases, few people seek care, but in the U.S., reports of norovirus-related outbreaks—two or more illnesses from a common source—this winter promise to far outstrip the 2500 typically seen. Cruise ships are being hit hard, too. In the United Kingdom, labs that test for the virus reported 63% more positive samples in the last 2 weeks of 2024 than the average, and hospitalizations were up 11%.

 

Albert Kapikian at the U.S. National Institutes of Health discovered the first norovirus in 1972 from an outbreak of “winter vomiting disease” that occurred at an elementary school in Norwalk, Ohio—hence the “noro” in the name. Scientists have since described more than 30 major variants that circulate in humans, distinguished by changes in their surface protein, VP1, which is the main target of antibodies that can “neutralize” it. “This virus is really good at getting around antibodies,” says veteran norovirus researcher Christine Moe of Emory University. “I used to think it was the most successful pathogen until COVID came along.” The world had four massive waves of norovirus between 2002 and 2012—“the most pandemics of any virus in the 21st century,” says UNC’s Ralph Baric, who has long studied the pathogen. Each erupted when a new norovirus variant replaced the dominant one. But since 2012, a set of related variants called GII.4 has held sway. “One of the hottest topics in norovirus research is why, after having those really frequent replacement events, has that process slowed down?” says Lindesmith, who works in Baric’s lab. A change that could help explain this winter’s surge in cases is the success of GII.17, a variant that has circulated at low levels for decades. GII.17 began to rise in the U.S. and six European countries last year, a 26 September 2024 paper in Eurosurveillance reported. According to the U.S. Centers for Disease Control and Prevention, 70% of 56 viral isolates sequenced between 1 September and the end of the year belong to the GII.17 lineage. The U.K. and the Netherlands are also seeing GII.17 dominate. Whether it will end GII.4’s 12-year reign as the dominant variant won’t be clear for many months.

 

What finally gave GII.17 an edge isn’t clear. Norovirus research Miranda de Graaf at the Erasmus Medical Center says the virus found in the Netherlands has significantly mutated away from other GII.17 strains. The drop in norovirus transmission because of social distancing during the COVID-19 pandemic may also have played a role. “If you go 3 or 4 years without much exposure in the population, the prediction would be that that background immunity is going to drop over time, and then there’s going to be a big surge that occurs sometime after as things return to normal,” Baric says. A norovirus vaccine likely would have a large global market among all ages, but development was slow off the mark. “It took a long time for people to recognize that these viruses really are infecting a lot of people,” Estes says, which limited funding for the research. The virus is also a challenge to work with; it can only grow reliably in a complicated organoid culture system, developed by Estes and co-workers, that mimics human intestines. The most advanced vaccine candidate, which contained “viruslike particles” made of VP1, failed in an efficacy trial in infants, its manufacture, HilleVax, reported in July 2024. A Chinese company, Zhifei, has an efficacy trial underway in children of a candidate that contains VP1s from four genotypes, including GII.4 and GII.17. And Moderna in September 2024 launched an efficacy trial in adults of a vaccine that uses messenger RNAs encoding VP1s from multiple variants (although not GII.17). Even if a norovirus vaccine proves safe and effective, it is up against what Baric calls “one of the most infectious viruses in nature,” which means a vaccine is unlikely to prevent all symptoms and completely stop transmission. It would probably also require regular boosters. “This is not going to be a one-and-done sort of vaccination,” Lindesmith says. But like COVID-19 vaccines, a norovirus vaccine might slow spread and spare people from severe disease or even death—keeping one day of misery from turning into something much worse.

 

doi: 10.1126/science.zapmdgv 


Via Juan Lama
No comment yet.
Mucosal Immunity
The largest immune tissue in the body
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
December 27, 2013 10:35 AM
Scoop.it!

Mucosal Immunity

is the most recent part of Immunology!

It appeared less than 40 years ago, while systemic immunity exploded 60  years ago.

It is still a minor part of Immunology teaching and research, while the mucosal immune system is at the frontline of encounters with germs, antigens... in other words the environment.

 

major keywords:

> 450 posts IgA http://www.scoop.it/t/mucosal-immunity?q=IgA

> 125 posts tolerance http://www.scoop.it/t/mucosal-immunity?q=tolerance

> 400 posts : microbiome http://www.scoop.it/t/mucosal-immunity?q=microbiome

 

july 2015: almost 2100 scoops, >1700 visitors, >3900 views

november 2017 >10K views of >3300 scoops

june 2020 >17.6K views, >5.5K visitors,  >4.5K scoops

may 2024 >22K views, >6.9 visitors,  >5.2 scoops

Gilbert C FAURE's insight:

This topic complements the more general Immunology topic.

 http://www.scoop.it/t/immunology

 

It includes also reproductive immunology (#100posts) searchable on

http://www.scoop.it/t/mucosal-immunity?q=reproductive

https://www.scoop.it/t/mucosal-immunity/?&tag=REPRODUCTION

 

and  also covers lung immunology (>325 posts)

http://www.scoop.it/t/mucosal-immunity?q=lung

 

Covid (>200 posts) can be found on 

https://www.scoop.it/topic/mucosal-immunity?q=covid

 

Vaccines are available on

https://www.scoop.it/topic/mucosal-immunity?q=vaccines

 

No comment yet.
Scooped by Gilbert C FAURE
October 15, 4:44 AM
Scoop.it!

Nasal Vaccines and the Future of Immunization | ASM.org | Stéphane Paul

Nasal Vaccines and the Future of Immunization | ASM.org | Stéphane Paul | Mucosal Immunity | Scoop.it
https://lnkd.in/drB_Y9mh
No comment yet.
Scooped by Gilbert C FAURE
October 7, 10:55 AM
Scoop.it!

B cells in inflammatory bowel disease - ScienceDirect

Inflammatory bowel diseases (IBD) have traditionally been considered T cell-driven disorders; however, accumulating evidence challenges this view and …
No comment yet.
Scooped by Gilbert C FAURE
October 6, 6:05 AM
Scoop.it!

A mother's touch: microbial guardians of early immune imprinting

No comment yet.
Scooped by Gilbert C FAURE
October 3, 4:03 AM
Scoop.it!

JCI - The complement system in intestinal inflammation and cancer

JCI - The complement system in intestinal inflammation and cancer | Mucosal Immunity | Scoop.it
Horowitz A, et al. Paracellular permeability and tight junction regulation in gut health and disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):417–432.View this article via: CrossRef PubMed Google Scholar Turpin W, et al.
No comment yet.
Scooped by Gilbert C FAURE
September 19, 10:52 AM
Scoop.it!

Conference: Harnessing airway immunity for next-gen vaccines

Conference: Harnessing airway immunity for next-gen vaccines | Mucosal Immunity | Scoop.it
Event by Novo Nordisk Foundation Science Cluster Conference: Harnessing airway immunity for next-gen vaccines The 32nd Science Cluster Conference, "Harnessing airway immunity for next-gen vaccines", will feature world leaders exploring the latest advancements in airway immunity and innovative...
Gilbert C FAURE's insight:

250 posts on mucosal vaccines

https://www.scoop.it/topic/mucosal-immunity?q=vaccines

 

No comment yet.
Scooped by Gilbert C FAURE
September 12, 4:38 AM
Scoop.it!

Rapid group-2 innate lymphoid cell mobilization from the intestine aids in early lung defense and repair

No comment yet.
Scooped by Gilbert C FAURE
September 9, 7:38 AM
Scoop.it!

Lactobacilli biology, applications and host interactions | Nature Reviews Microbiology

Lactobacilli biology, applications and host interactions | Nature Reviews Microbiology | Mucosal Immunity | Scoop.it
Lactobacilli encompass more than 300 species, spanning 25 genera, found in the microbiomes of humans, animals and plants with relevance in agriculture, foods and medicine. Lactobacilli comprise all bacteria previously assigned to the Lactobacillus genus and, similar to other lactic acid bacteria, are characterized by their saccharolytic, fermentation-energy metabolism and diverse enzymatic pathways that support redox balance and maintain intracellular pH. Some lactobacilli are pervasive in dairy, meat and plant foods, where they either contribute to spoilage and food waste or are desired and necessary for the production of fermented foods and animal feed. Strains of lactobacilli are the most applied probiotics tested in clinical studies. The study of host-associated intestinal and vaginal microbiomes has demonstrated that lactobacilli drive epithelial and immune cell responses, resulting in mainly beneficial effects on host health. This Review explores both established and emerging concepts related to this group of microorganisms. It highlights central tenants of their genetic diversity, metabolism, stress tolerance and distribution across host-associated microbiomes, as well as their importance in fermented foods and in health modulation as probiotics. With this accumulated knowledge, there remain substantial opportunities for expanded application of lactobacilli across different domains relevant to food production and health. Lactobacilli are important members of human, animal and insect microbiomes and are prominent in food fermentations. In this Review, Mejía-Caballero and Marco explore the diversity of lactobacilli, focusing on their fundamental traits and their applications in foods and medicine.
No comment yet.
Scooped by Gilbert C FAURE
August 21, 8:37 AM
Scoop.it!

Intestinal tuft cell subtypes represent successive stages of maturation driven by crypt-villus signaling gradients - Nature Communications | Stéphane Paul

Intestinal tuft cell subtypes represent successive stages of maturation driven by crypt-villus signaling gradients - Nature Communications | Stéphane Paul | Mucosal Immunity | Scoop.it
https://lnkd.in/dYd7jWuK
No comment yet.
Scooped by Gilbert C FAURE
August 12, 10:12 AM
Scoop.it!

https://jamanetwork.com/journals/jama/fullarticle/2837543?guestAccessKey=3993430c-f995-4116-a1d2-bfdc2409db51&utm_source=linkedin_company&utm_medium=social_jama&utm_term=17856895622&utm_campaign=ar...

No comment yet.
Scooped by Gilbert C FAURE
August 11, 2:18 PM
Scoop.it!

Timeline of major research and development milestones related to the microbiome | William Wallace, Ph.D

Timeline of major research and development milestones related to the microbiome | William Wallace, Ph.D | Mucosal Immunity | Scoop.it
Timeline of major research and development milestones related to the microbiome

Here’s a snapshot of how we got from Antonie van Leeuwenhoek’s first look at microbes to the "multi-omics era" shaping personalized medicine today:

📜 1670s – Antonie van Leeuwenhoek observes microorganisms for the first time.
🌱 1729 – Pier Antonio Micheli pioneers fungal classification.
🦠 1880s–1900s – Robert Koch formalizes germ theory; Alfred Nissle isolates the first probiotic E. coli strain.
💊 1928 – Alexander Fleming discovers antibiotics.
🧫 1958 – Ben Eiseman reports success with fecal microbiota transplants (FMT) in treating C. difficile.
🧪 1972 – First germ-free mice raised to study host–microbe interactions.
🧬 1995 – First complete bacterial genome sequenced (Haemophilus influenzae).
🌍 2007 – Human Microbiome Project launched.
🔄 2013 – FMT enters modern clinical practice for recurrent C. difficile.
🧠 2016–2020 – Studies link microbiota to cancer therapy response, depression, and gut–brain signaling.
🧷 2022 – Metagenome-assembled genomes expand our catalog of microbial diversity; dietary flavonoids shown to alleviate depressive symptoms.

https://lnkd.in/gqrz3nUD
No comment yet.
Scooped by Gilbert C FAURE
August 7, 1:49 PM
Scoop.it!

Single cell transcriptional analysis of human adenoids identifies molecular features of airway microfold cells

No comment yet.
Scooped by Gilbert C FAURE
August 4, 11:07 AM
Scoop.it!

https://www.mucosalimmunology.org/article/S1933-0219(25)00078-9/fulltext

No comment yet.
Scooped by Gilbert C FAURE
October 15, 4:46 AM
Scoop.it!

JCI - Interferon-γ is a direct driver of crypt hyperplasia in celiac disease

JCI - Interferon-γ is a direct driver of crypt hyperplasia in celiac disease | Mucosal Immunity | Scoop.it
Crypt hyperplasia is a key feature of celiac disease and several other small intestinal inflammatory conditions. Analysis of the gut epithelial crypt zone by mass spectrometry-based tissue proteomics revealed a strong interferon-γ (IFN-γ) signal in active celiac disease.
No comment yet.
Scooped by Gilbert C FAURE
October 13, 4:57 AM
Scoop.it!

Inhalable materials and biologics for lung defence and drug delivery | Nature Reviews Materials

Inhalable materials and biologics for lung defence and drug delivery | Nature Reviews Materials | Mucosal Immunity | Scoop.it
Airway mucus has a crucial role in protecting against inhaled pathogens and regulating water homeostasis, but it can also diminish the efficacy of therapeutic pulmonary delivery. Recent development in inhalable materials and biologics has introduced strategies to modify mucus properties, strengthening mucosal protection, advancing drug delivery and targeting and supporting effective water regulation. In this Review, we thoroughly examine the structure and function of airway mucus, along with the challenges and opportunities it presents for inhaled treatments. We explore new methods that enhance the protective role of mucus through physical reinforcement, pathogen neutralization, muco-trapping and rehydration, as well as strategies that overcome the mucus barrier to improve drug delivery, including physical modulation, mucoadhesive design, muco-penetrating design, mucolytics and active targeting. Finally, we discuss the clinical implications of these promising strategies, emphasizing the need to balance mucosal function with optimized therapeutic delivery. We seek to explore prospective ways to improve inhalation therapies for both infectious and chronic lung diseases by reviewing recent progress in inhalable materials and biologics. Airway mucus complicates treatment of respiratory disease by both defending the lungs and hindering inhaled drugs to cross the barriers. This Review explores translational advances in inhalable materials and biologics that enhance mucus protection or drug penetration.
No comment yet.
Scooped by Gilbert C FAURE
October 7, 4:28 AM
Scoop.it!

What Lives In Fog?

What Lives In Fog? | Mucosal Immunity | Scoop.it
“A fog droplet isn’t a bad environment to live in"
No comment yet.
Scooped by Gilbert C FAURE
October 6, 2:00 AM
Scoop.it!

New research reveals the cervix as a truly immunocompetent tissue

New research reveals the cervix as a truly immunocompetent tissue | Mucosal Immunity | Scoop.it
Cervical epithelial cells are far from passive bystanders in the body's immune system. New research shows they actually play an active and highly coordinated role in detecting and fighting infections.
No comment yet.
Scooped by Gilbert C FAURE
September 26, 12:52 PM
Scoop.it!

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | Newswise

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | Newswise | Mucosal Immunity | Scoop.it
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy...
No comment yet.
Scooped by Gilbert C FAURE
September 13, 1:46 PM
Scoop.it!

A User’s Guide to Designing Efficient and Safe Mucosal Vaccines: Challenges & Potentials

No comment yet.
Scooped by Gilbert C FAURE
September 11, 1:06 PM
Scoop.it!

#poultry #animalhealth #vaccination #veterinary #sops #poultryfarming | Dr. Hamza Shabbir DVM

#poultry #animalhealth #vaccination #veterinary #sops #poultryfarming | Dr. Hamza Shabbir DVM | Mucosal Immunity | Scoop.it
🚰🐔 Drinking Water Vaccination in Poultry – Proper SOPs for Success

Mass vaccination of a flock via drinking water is one of the most practical, less stressful, and commonly used methods in poultry farms. But to achieve protection against diseases, strict SOPs must be followed.

Here’s a complete overview 👇

---

1️⃣ Drinking Water Vaccination

The goal is simple: every bird in the flock must receive the correct vaccine dose.

✅ Calculate water intake based on bird age (see standard tables).
✅ Vaccine water should be consumed within 1.5–2 hours.
✅ Withhold water for 1 hour before vaccination to encourage uniform drinking.
✅ Neutralize chlorine/heavy metals in water (using skimmed milk powder or vaccine stabilizer).


2️⃣ Storage & Transportation of Vaccine

📦 Vaccines must be handled with extreme care:

Store at 2–8°C (35–46°F) in a dedicated fridge.

Transport in a cool box with ice packs, keeping 4–8°C constant.

Only transport the required doses.


🛠️ Equipment Needed:

Clean container (80L approx.)

Vaccination can/water proportioner (5–10L)

Measuring jug, bucket, stirrer

Skimmed milk (stabilizer)


💡 Administration Steps:

1. Prepare vaccines on a clean surface using disposable gloves.


2. Neutralize chlorine (stock solution, 20 min wait).


3. Mix vaccine gently in water and distribute evenly.


4. Ensure all drinkers/nipples are filled before lowering.


5. Walk the flock to encourage uniform drinking.


6. Vaccine water must be consumed within 2 hours.
---

3️⃣ Evaluation of Drinking Water Vaccination

After vaccination, it’s critical to check how well the flock received the vaccine:

🔹 Dye Test: Add dye tablets with vaccine water. Birds’ tongues should stain blue. At least 90% of sampled birds should show staining.
🔹 Serology (ELISA/HI): Take blood samples from 20 random birds after ~3 weeks to measure antibody titers.

📊 Good Response Indicators:

High antibody titers

Coefficient of variation (CV) < 50%

Uniform flock immunity

---

✅ Conclusion

Drinking water vaccination is simple, quick, and flock-friendly. When SOPs are followed properly—from storage → preparation → administration → evaluation—the benefits are clear:
✔️ Better growth & weight gain
✔️ Higher egg production
✔️ Improved uniformity
✔️ Stronger disease resistance
---

💬 What’s your experience with drinking water vaccination in poultry?

#Poultry #AnimalHealth #Vaccination #Veterinary #SOPs #PoultryFarming

No comment yet.
Scooped by Gilbert C FAURE
September 4, 11:54 AM
Scoop.it!

Mechanisms and implications of epithelial cell plasticity in the bladder | Nature Reviews Urology

Mechanisms and implications of epithelial cell plasticity in the bladder | Nature Reviews Urology | Mucosal Immunity | Scoop.it
Cellular plasticity, the ability of cells to reprogramme and alter their fate, has a pivotal role in maintaining homeostasis and facilitating tissue regeneration after injury. The bladder urothelium, a dynamic transitional epithelial layer, displays a highly plastic phenotype that enables its remarkable regenerative capacity in response to wounding. During both development and repair, urothelial cells exhibit considerable plasticity through processes such as dedifferentiation, transdifferentiation and epithelial-to-mesenchymal transition. Urothelial plasticity is not only crucial for healthy tissue repair but is also involved in pathological conditions, including cancer. In bladder tumorigenesis, urothelial cells exploit plasticity to acquire new phenotypic and functional characteristics, transitioning between distinct cellular states. This plasticity contributes to tumour heterogeneity, subtype switching, progression, metastasis and resistance to therapies. These dynamic cellular transitions are regulated by intrinsic and extrinsic factors, including transcriptional and epigenetic mechanisms, as well as microenvironmental influences. Targeting urothelial plasticity could offer novel therapeutic strategies for bladder-related diseases. In this Review the authors describe current knowledge on cellular plasticity in the bladder urothelium, emphasizing its role in bladder repair and tumorigenesis, and explore the molecular mechanisms of urothelial plasticity and discuss its potential as a novel therapeutic target for bladder-related diseases.
No comment yet.
Scooped by Gilbert C FAURE
August 12, 3:25 AM
Scoop.it!

The human skin microbiome: from metagenomes to therapeutics | Nature Reviews Microbiology

The human skin microbiome: from metagenomes to therapeutics | Nature Reviews Microbiology | Mucosal Immunity | Scoop.it
The skin microbiome is composed of a diverse community of microorganisms, including bacteria, fungi, viruses and mites. These microorganisms have a crucial role in maintaining skin health, protecting against pathogens and modulating immune responses. In recent years, our understanding of the skin microbiome has expanded substantially with the deployment of metagenomic sequencing. This technology, by reconstructing microbial species, strains and gene pathways in the microbiomes of different cohorts, has led to identification of numerous therapeutic targets and thus propelled the development of therapeutic approaches that are aimed at leveraging these microorganisms to treat skin conditions and to improve skin health. In this Review, we discuss the composition, ecology, functions and therapeutic horizons of the human skin microbiome, presenting examples of studies that highlight potential therapeutic targets in the skin microbiome, ongoing progress in the development of skin microbiome-based therapeutics and challenges. In this Review, Oh and Voigt explore the major characteristics and functions of the skin microbiome, and they highlight potential therapeutic targets in the skin microbiome and ongoing progress in the development of skin microbiome-based therapeutics.
No comment yet.
Scooped by Gilbert C FAURE
August 8, 3:38 AM
Scoop.it!

IL-21 conditions antigen-presenting human γδ T-cells to promote IL-10 expression in naïve and memory CD4+ T-cells

No comment yet.
Scooped by Gilbert C FAURE
August 5, 5:05 AM
Scoop.it!

STI Vaccines at #STIHIV2025 #IUSTI #ISSTDR | Jason Ong

STI Vaccines at #STIHIV2025 #IUSTI #ISSTDR | Jason Ong | Mucosal Immunity | Scoop.it
STI Vaccines at #STIHIV2025 #IUSTI #ISSTDR

Professor Helen Rees
- HPV Vaccine uptakes rising with move to 1-dose and the pipeline of therapeutic HPV vaccines promising
- Syphilis vaccine candidates but all preclinical phase
- Herpes simplex vaccine candidates - preclinical phase
- Gonorrhoea - 4CMenB may be useful (~30-40% effective)
- Chlamydia - preclinical phase.
- Trichomoniasis - preclinical phase.
- Mpox - 3 licensed vaccines (originally for small pox) - access remains an issue
- Vaccine hesitancy needs to be addressed. Convenience. Complacency. Convenience. Context.

Professor Sanjay Ram
- Chlamydia: "bacteria that thinks it is a virus".
majority would generate antibodies against chlamydia but does not affect chance of reinfection.
high titres of antibodies may be associated with greater complications (PID).
Mice model - CD4 cells are important for clearing genital infection.
- Syphilis
previous syphilis can alter course of subsequent episode of syphilis
- Gono
No immunity following gonococcal infection.
Intravacc (intranasal) vaccine, LimmaTech Biologics "6-in-1" vaccine might be promising.
No comment yet.
Scooped by Gilbert C FAURE
July 28, 9:55 AM
Scoop.it!

Throughout life, everyone is exposed to foreign antigens that enter the body through the skin, lungs, and gut. | Science Magazine

Throughout life, everyone is exposed to foreign antigens that enter the body through the skin, lungs, and gut. | Science Magazine | Mucosal Immunity | Scoop.it
Throughout life, everyone is exposed to foreign antigens that enter the body through the skin, lungs, and gut. In particular, early life sees the ingestion of many new types of food and encounters with microbes that colonize mucosal tissues. How immune systems learn to “tolerate” foreign antigens, yet remain quickly responsive to other threats such as pathogenic viruses and bacteria, remains an unsolved problem in immunology.

In a new Science study, researchers describe a key piece of the puzzle. The authors identify a subtype of antigen-presenting cells (APCs) in the mesenteric lymph nodes in mice that help train regulatory T cells (Treg cells) to suppress inflammatory responses to food antigens in the period around weaning. The identification of this APC subtype potentially opens the door to the development of therapies for food-associated allergies and inflammatory diseases.

Learn more in a new #SciencePerspective: https://scim.ag/44zUUSK | 10 comments on LinkedIn
No comment yet.